CheckMate trials 648 and 649 explored various chemotherapy strategies for ESCC and GI cancer treatment. Syma Iqbal, MD: CheckMate 649 was a randomized trial for patients with untreated esophageal GEJ ...
CheckMate -648 marks the third global trial in which Opdivo demonstrated a significant benefit for patients with upper gastrointestinal cancers Data to be featured in an oral presentation during the ...
Swallowable sampling device combined with methylation biomarker panel IDs Barrett esophagus. The approvals are based on data from the phase 3 CheckMate-648 trial, which included 970 adults with ...
Bristol Myers Squibb announced positive topline results from the phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) in ...
This trial is no longer recruiting patients. We hope to add results when they are available. Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results